Northera Survives Questions About Benefit Of Dizziness Endpoint At Advisory Panel

Members of the Cardiovascular and Renal Drugs Advisory Committee accepted improvement in dizziness is a reasonable endpoint for measuring a drug’s benefit in treating symptomatic neurogenic orthostatic hypotension Jan. 14 as they voted 16-7 in favor of approving Chelsea Therapeutics International Ltd.’s Northera (droxidopa) for NOH.

Dizziness “is kind of the core patient-oriented measure” of what matters to those with the disease, noted Vanessa Hinson, Medical University of South Carolina.